

Improving the accuracy and turn-around time of controlled drug prescribing for patients being discharged home for end-of-life care

Suzanne Daniel, Janki Patel, Debbie Benson
 Conquest Hospital, East Sussex Healthcare NHS Trust, England

Abstract

Many patients approaching the end of their life express the preference to die at home,[1] although unfortunately the majority of people will still die in hospital.[2] For patients approaching the end of their life, it was noted anecdotally that often those who have expressed a preference to go home from hospital for end of life care may have their discharge delayed due to problems in the prescribing of common medications used to alleviate distressing symptoms at the end of life.

An initial audit at Conquest Hospital showed an 89% error rate in these prescriptions, mostly related to prescribing controlled drugs such as morphine and midazolam. A single standardised dispensing chart for commonly prescribed medications at the end of life, in the form of both "Just in Case" medications and syringe driver medications, was created which addressed this problem by having the medications pre-written so as to meet all legal requirements for controlled drugs. The prescriber is able to choose and fill out an appropriate drug and dose by using flow-chart information overleaf and then sign the prescription to allow it to be dispensed. After an initial two month pilot period, a re-audit showed a significant fall in error rate down to 11%, as well as an improvement in turnaround time in dispensing the medications.

Problem

In the last few days of life, a patient may no longer be able to swallow their oral medications and may require parenteral medications to manage symptoms such as pain, nausea and vomiting, respiratory secretions, and agitation. These symptoms can often be anticipated, and if a patient has expressed a preference to die at home and is leaving hospital then anticipatory injectable medication, or "Just in Case" medications, can be dispensed at discharge for administration in by appropriately trained community nurses.

Some of these medications will be controlled drugs. The current process for the prescription of these drugs for palliative patients that are waiting discharge home from East Sussex Healthcare NHS Trust (ESHT), England, is open to a number of sources of error, and these have knock-on effects against achieving a safe and quick discharge for these patients. While all other medications can be ordered electronically via the medicines management system, a prescription for a controlled drug must be dispensed from a drug chart. If an incorrectly written controlled drug prescription is sent to pharmacy, the pharmacist will contact the prescribing doctor and make arrangements for amendments to be made. This may be via transferring the drug chart back to the ward or the doctor coming to pharmacy to amend it, or the pharmacist trying to find the doctor themselves to make the relevant amendments.

As these discharge medications are written onto the patients usual inpatient drug chart, sending the chart to the pharmacy department means that the patient is on the ward without their drug chart while the prescription error is corrected or is being dispensed. Consequently the patient is unable to have any of their regular or "as required" medications during that time.

Additionally, there is a lack of standardisation within ESHT as to the choice, doses and the quantity to be supplied of these agents. It is recognised that there needs to be flexi-

bility for individual patients, especially in the prescribing of opiates or in the event of renal impairment. However, guidelines for several of the "Just in Case" medications would be useful for those patients who are being discharged for terminal care in the community.

Background

End of life care refers to the management of patients during their last few days, weeks, or months of life. Although 63% of people express a preference to die in their own home,[1] only 19% of people will do so, and 58% of deaths in England occur in hospital.[2]

The NICE quality standard for end of life care for adults sets out markers of high quality care for adults aged 18 years and older with advanced, progressive, incurable conditions. It aims to contribute to the following outcomes for people approaching the end of life:

- The care that people approaching the end of life receive is aligned to their needs and preferences
- Increased length of time spent in preferred place of care during the last year of life
- Reduction in unscheduled care hospital admissions leading to death in hospital (where death in hospital is against their stated preference).[3]

Some of the "Just in Case" medications that may be used to gain symptom control for a patient as they are deteriorate, and frequently the drugs used in syringe drivers, will be controlled drugs that have

BMJ Quality Improvement Reports

tighter regulations regarding their use, storage, and prescription requirements. A prescription for a controlled drug has important differences as to how it is written compared to regular prescriptions, and legally must contain the following details:

- The patient's full name, address, and age (if under 12 years old)
- The name and form of the drug, even if only one form exists
- The strength of the preparation
- Specific instructions on the dose to be taken
- The total quantity (in words and figures) or total number of dosage units (in words and figures) of the drug to be supplied.[4]

Baseline measurement

In conjunction with the palliative care team and pharmacy department, over a two week period we identified all patients going home from Conquest Hospital for end of life care with a "Just in Case" prescription. We developed an audit proforma for use within the pharmacy department and measured the drug and doses prescribed, any sources of error, and the time taken from the prescription arriving in the pharmacy department to medications being released to the ward.

Nine patients were discharged home from hospital for end-of-life care during the two week audit period with prescriptions for 'Just in Case' medications. Eight of the nine prescriptions (89%) contained at least one prescription error which required amending prior to the prescription being dispensed by the pharmacy department. The average turnaround time for a prescription to be dispensed was 1 hour and 25 minutes.

The most common prescription error (67%) was missing information regarding the strength of the drug being prescribed. The legal requirement to write the total quantity of a controlled drug to be supplied in both words and figures was only written in 44% of prescriptions. Other errors noted were the frequency of dosing missed (33%), patient details missing (22%), and prescriber signature missing (11%).

Design

To rectify these problems we developed a standardised dispensing chart for commonly prescribed medications at the end of life (see appendix 1). The chart allows a single form to be completed for either (or both) "Just in Case" medications and syringe driver medication, should the patient require them. The chart is written clearly with the names of the first-choice drugs to treat pain, nausea and vomiting, anxiety, confusion or restlessness, and respiratory secretions, with spaces for the prescribing doctor to fill out the dose required and sign the prescription. Overleaf, flow-diagram information is provided on how to pick a suitable dose. Controlled drugs are written so as to meet all legal prescribing requirements providing that the prescriber fills in all the blanks.

The dispensing chart is easily recognisable and is given priority through the pharmacy department to allow a more rapid dispensing process. The creation of a separate dispensing chart for end of life medications also allows the patient's regular inpatient chart to stay with them on the ward while their discharge medications are being prepared, meaning they can receive their regular medications and any "as required" medications during this time.

Strategy

A 'Plan Do Study Act' approach was implemented and the chart was amended following feedback from users. The majority of changes related to small administrative improvements, for example by providing spaces for the patient's ward and consultant, and for pharmacy staff to sign at the various dispensing stages. The recommended dose of haloperidol was also changed following consultation with the palliative care consultant.

See supplementary file: ds3826.pdf - "End of life drug dispensing chart"

Post-measurement

After a two month pilot period, we re-audited using the same audit proforma that had been implemented during our baseline measurements. During the fourteen days of data collection there were nine prescriptions received by the pharmacy department on the new standardised dispensing chart.

Only one of these prescriptions (11%) had an error requiring correction, which was where the prescribing doctor had not filled out the gap to detail the strength of diamorphine to be dispensed. The average time for dispensing the medications was 60 minutes.

All prescriptions received met legal requirements for controlled drug prescribing in terms of having the full patient details and total quantity supplied in both words and figures.

Lessons and limitations

A major limitation of this project was the small sample size of the audits, which reflects that there are only a reasonably small number of people who go home from hospital for end of life care. People may alternatively decide that they wish to die in hospital or at a hospice, or unfortunately may not have the opportunity or capacity to express their preference so consequently would not benefit from our drug dispensing chart.

The frequent turnover of house officers and senior house officers, who were identified in our audit as the most frequent prescribers for end of life medications, also means that staff training on the dispensing charts has to be ongoing. To address this, sessions on the charts and controlled drug prescribing in general have been added to the compulsory local F1 and F2 teaching schedule.

Conclusion

Despite there being a relatively small number of people who do go home from hospital for end of life care, any intervention that makes this process smoother and safer is valuable. Anecdotal observations had been made that the process of dispensing medications for these patients was often delayed due to errors in the prescription of controlled drugs, and an initial audit supported this view by identifying that 89% of end-of-life prescriptions contained at least one error. The majority of these errors related to meeting the legal requirements for the prescription of controlled drugs.

To rectify this, we created a standardised drug dispensing chart for end of life medications which met all legal requirements for controlled drugs prescriptions as well as providing easy to follow guidance on drug choice and dose to be started on. Re-audit after a pilot period showed a significant improvement in both error rate and dispensing time of these medications. This then allowed for better use of staff time within the pharmacy department, and a smoother and safer discharge for our patients going home for end of life care.

References

1. National End of Life Care Intelligence Network. Variations in place of death in England. Bristol: National End of Life Care Intelligence Network; 2010.
2. Gomes B, Calanzani N, Higginson I. Local preferences and place of death in regions within England 2010. London: Cicely Saunders International; 2011.
3. National Institute for Health and Care Excellence. Quality standard for end of life care for adults. Aug 2011 (modified October 2013). London: National Institute for Health and Clinical Excellence; 2013.
4. Joint Formulary Committee. British National Formulary 66. London: BMJ Group & Pharmaceutical Press; 2013.

Declaration of interests

None.

Acknowledgements

Dr Elena Mucci, ESHT acute specialist palliative care nurses (Conquest site).

Pas Label

Drug dispensing chart

For hospital pharmacy dispensing of medications for use in patients going home for end-of-life care. Please also complete the 'Drug Instruction Chart' for community instructions on drug titration. See guidance overleaf for standard doses to be administered PRN and/or via syringe drivers. **This chart is only to be completed by an authorised prescriber.**

Ward _____ Bleep/Grade _____
Consultant _____ Date _____

Drugs for syringe driver By Continuous Subcutaneous Infusion

Drugs for PRN injections (sc/IM) (if frequent doses are needed consider r/v by a doctor)

PAIN

DIAMORPHINE (___ MG/AMP) 
Dose _____ MG over 24 hours
Please supply TEN (10) AMPS
Signature _____
Print Name _____

OR

Other if NOT Diamorphine 
Drug _____
Strength _____
Dose _____ MG over 24 hours
Please supply TEN (10) AMPS
Signature _____
Print Name _____

DIAMORPHINE (___ MG/AMP) 
_____ MG every _____ hours
Please supply TEN (10) AMPS
Signature _____
Print Name _____

OR

Other if NOT Diamorphine 
Drug _____
Strength _____
Dose _____ MG every _____ hours
Please supply TEN (10) AMPS
Signature _____
Print Name _____

Please note that Diamorphine comes in the following strengths - 5mg / 10mg / 15mg / 30mg / 100mg – please R/V the dose and consider the correct strength when prescribing.

NAUSEA & VOMITING

HALOPERIDOL (5MG/1ML)
Dose _____ MG over 24 hours
(10 AMPS)
Signature _____

AND/OR

Drug _____
Dose _____ MG over 24 hours
(10 AMPS)
Signature _____

HALOPERIDOL (5MG/1ML)
Dose _____ MG every _____ hours
(10 AMPS)
Signature _____

AND/OR

Drug _____
Dose _____ MG every _____ hours
(10 AMPS)
Signature _____

ANXIETY, CONFUSION OR RESTLESSNESS

MIDAZOLAM (10MG/2ML AMP) 
Dose _____ MG over 24 hours
Please supply TEN (10) AMPS
Signature _____
Print Name _____

OR

Drug _____
Dose _____ MG over 24 hours
(10 AMPS)
Signature _____

MIDAZOLAM (10MG/2ML AMP) 
Dose _____ MG every _____ hours
Please supply TEN (10) AMPS
Signature _____
Print Name _____

OR

Drug _____
Dose _____ MG every _____ hours
(10 AMPS)
Signature _____

RESPIRATORY SECRETIONS

HYOSCINE HYDROBROMIDE
Dose _____ MG over 24 hours
(10 AMPS)
Signature _____

OR

GLYCOPYRRONIUM
Dose _____ MG over 24 hours
(10 AMPS)
Signature _____

HYOSCINE HYDROBROMIDE
Dose _____ MG every _____ hours
(10 AMPS)
Signature _____

OR

GLYCOPYRRONIUM
Dose _____ MG every _____ hours
(10 AMPS)
Signature _____

WATER & other S/C infusions

WATER FOR INJECTION / 20*10ml amps. MDU. Signature _____
OTHER _____

WATER FOR INJECTION / 20*10ml amps. MDU. Signature _____
OTHER _____

Please contact the Palliative care team Conquest ext. (14) 8787, bleep 2616 or 2234) or Medicines Information ext. (14) 7067 for further advice

EDGH ext.(13) 3788, bleep 0485 or 0948, Medicines Information ext. (13) 3785

Pharmacy

CC _____
Dispensed _____
EC _____

Guidelines for symptom control

Nausea and Vomiting

Is nausea or vomiting present?

Yes

No

HALOPERIDOL
0.5 – 1.5mg S/C PRN (Max
8 hourly) and give stat dose

HALOPERIDOL
0.5-1.5mg S/C
PRN (Max 8 hourly)

Supportive information:

- If the patient is already taking regular antiemetics contact the palliative Care team for advice
- If symptoms persist contact the Palliative Care Team

Consider use of
continuous S/C infusion of
HALOPERIDOL, 2.5-5mg
/ 24 hr (Max. 10mg / 24hr)

Agitation and Terminal Restlessness



Are there signs of agitation / distress?

Yes

No

Exclude all reversible
causes before considering
medication (see below)

MIDAZOLAM 2.5-
5mg S/C PRN (Max.4
hourly)

MIDAZOLAM 2.5-5mg
S/C PRN (Max. 4 hourly
and give stat dose
AND
Consider starting
continuous infusion S/C
MIDAZOLAM 10mg/
24hr (5mg in frail
elderly)

If two or more doses of
prn MIDAZOLAM
required then consider
a continuous infusion
S/C over 24 hrs

Supportive information:

- Please ensure all reversible causes of agitation have been ruled out before administering medication (eg urinary retention, pain)
- If symptoms persist contact the Palliative Care Team
- It is good practice to inform those closest to the patient when medication will be used to assist in symptom control in severe agitation. The sole aim of medication is symptom control and not to hasten death.

Respiratory tract secretions

Is there evidence of excessive secretions?

Yes

No

HYOSCINE HYDROBROMIDE
0.4mg S/C PRN (max. 4 hourly)
AND
Start continuous S/C infusion of
HYOSCINE HYDROBROMIDE
1.2mg over 24 hr.

HYOSCINE HYDROBROMIDE
0.4mg S/C PRN (Max. 4 hourly)

If two or more doses or prn
HYOSCINE HYDROBROMIDE
required then consider a continuous
infusion 1.2mg S/C over 24 hours

If no response after 24 hours,
increase S/C infusion of
HYOSCINE HYDROBROMIDE
To 2.4mg over 24 hrs

Supportive information:

- HYOSCINE HYDROBROMIDE can be sedating, if sedation is not acceptable use GLYCOPYRRONIUM 0.4mg S/C PRN or 1.2mg/ 24hr in an infusion
- If symptoms persist contact the Palliative Care Team

Dyspnoea



Is patient breathless?

Yes

No

Is the patient on Oral
morphine already?

No

Yes

Diamorphine
1.25-2.5mg S/C PRN (Max
four hourly)

DIAMORPHINE 1.25-2.5mg
S/C PRN (Max 4 hourly) and
give stat dose.

AND

Commence low dose
DIAMORPHINE in continuous
S/C infusion 5-10mg/ 24hr.

Supportive Information:

- Consider non pharmacological interventions also – open a window, use a fan to circulate air
- IF THE PATIENT HAS SIGNIFICANT RENAL/LIVER FAILURE PLEASE CONTACT THE PALLIATIVE CARE TEAM
- If the patient is breathless & anxious consider Midazolam stat 2.5mg s/c prn
- If symptoms persist contact Palliative Care Team.

Pain

Yes

Is the patient experiencing pain?

No

Is the patient on
regular analgesia?

Yes



Yes

Is the patient on
regular analgesia?

No

DIAMORPHINE
2.5-5mg S/C
PRN (Max 4
hourly) and give
stat dose.
AND
Start S/C
infusion of
DIAMORPHINE
10mg/24hr (or
5mg/24hr in frail
elderly)

Convert regular analgesia to
equivalent dose of
DIAMORPHINE S/C/ over 24hr.
1. If on regular oral morphine,
or on other opioids please liaise
with
•Pharmacy
•Palliative care Team
OR consult the
•Palliative care handbook
2. Prescribe breakthrough PRN
dose which should be
equivalent to 1/6 of 24 hour
dose

DIAMORPHINE
2.5-5mg S/C PRN
(Max 4 hourly)

After 24hrs review
use of analgesia.
If 3 or more doss
required prn then
start a S/C
infusion over
24hrs.

After 24 hrs R/V response and titrate dose in S/C infusion according to pain levels and use of PRN analgesia

Supportive information:

- Always review a patient's needs, once on a syringe driver they may still need PRN doses given and the dose in the syringe driver may need to be reviewed.
- IF THE PATIENT HAS SIGNIFICANT RENAL/LIVER FAILURE PLEASE CONTACT THE PALLIATIVE CARE TEAM
- To convert from other strong opioids or if the patient has a fentanyl patch contact Palliative Care Team / Pharmacy for further advice & support .
- If symptoms persist contact Palliative Care Team.

General Guidance for Symptom control and prescribing

- Prescribe all PRN drugs for the end of life care whether the patient has symptoms or not
- Assessment of symptoms is an on going process and a multi-disciplinary responsibility
- All drugs mentioned in this guideline section could be mixed in one syringe: if more than 3 drugs being used however please contact the Palliative Care Team or Pharmacy.
- Once a continuous infusion is started you need to review it daily: the doses may need altered if symptoms are not controlled or if multiple PRN doses have been needed
- If you are not getting symptoms under control using this guidance please ask for advice day or night